Obesity Science
HT-6184 addresses one of the root causes of obesity-related metabolic dysfunction
HT-6184: A Targeted Approach to Addressing Obesity and Inflammation
Exploring Inflammation’s Role in ObesityHalia Therapeutics is investigating a therapeutic approach to obesity with HT-6184, a compound that targets the NLRP3 inflammasome, a key component in inflammation linked to metabolic diseases. Preclinical studies suggest that inhibition of NLRP3 may help reduce tissue inflammation, potentially addressing metabolic disturbances commonly observed in obesity, type 2 diabetes, and cardiovascular disease. 1,2,3 However, these findings remain investigational and require further clinical validation.One proposed mechanism by which HT-6184 may exert its effects is through macrophage polarization. In obesity, immune cells called macrophages may shift toward a pro-inflammatory (M1) state, contributing to chronic inflammation. HT-6184 may help to balance the ratio of M1 to M2 macrophages, which are associated with anti-inflammatory responses. Further studies are required to confirm this hypothesis in clinical settings.Investigational Status: HT-6184 is currently an investigational compound and is not approved for the treatment of obesity or any other condition. Halia Therapeutics is planning to conduct a phase 2 clinical trial evaluating the safety and efficacy of HT-6184 in combination with semaglutide for weight loss in adults who are obese or overweight with a weight-related comorbid condition.Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.